| Cell therapy industry: billion dollar global business with unlimited potential C Mason, DA Brindley, EJ Culme-Seymour, NL Davie Regenerative medicine 6 (3), 265-272, 2011 | 203 | 2011 |
| Peak serum: implications of serum supply for cell therapy manufacturing DA Brindley, NL Davie, EJ Culme-Seymour, C Mason, DW Smith, ... Regenerative medicine 7 (1), 7-13, 2012 | 166 | 2012 |
| A decade of cell therapy clinical trials (2000–2010) EJ Culme-Seymour, NL Davie, DA Brindley, S Edwards-Parton, C Mason Regenerative medicine 7 (4), 455-462, 2012 | 87 | 2012 |
| Streamlining cell therapy manufacture NL Davie, DA Brindley, EJ Culme‐Seymour Development 85, 100, 2012 | 44 | 2012 |
| The impact of market volatility on the cell therapy industry DA Brindley, BC Reeve, WA Sahlman, GA Bonfiglio, NL Davie, ... Cell Stem Cell 9 (5), 397-401, 2011 | 34 | 2011 |
| Knowledge translation in tri-sectoral collaborations: an exploration of perceptions of academia, industry and healthcare collaborations in innovation adoption SS Ii, L Fitzgerald, MM Morys-Carter, NL Davie, R Barker Health Policy 122 (2), 175-183, 2018 | 29 | 2018 |
| Promising growth and investment in the cell therapy industry during the first quarter of 2012 DA Brindley, NL Davie, WA Sahlman, GA Bonfiglio, EJ Culme-Seymour, ... Cell stem cell 10 (5), 492-496, 2012 | 19 | 2012 |
| Regenerative medicine through a crisis: Social perception and the financial reality D Brindley, N Davie Rejuvenation Research 12 (6), 455-461, 2009 | 17 | 2009 |
| Cell therapy manufacturing: identifying and meeting demand J Carmen, DA Brindley, NL Davie, D Smith Stem Cells in Regenerative Medicine: Science, regulation and business …, 2015 | 5 | 2015 |
| Quality control in cell and tissue engineering IB Wall, N Davie Standardisation in Cell and Tissue Engineering, 148-165, 2013 | 5 | 2013 |
| Academia-industry collaboration in translational medicine N Davie University of Oxford, 2016 | 1 | 2016 |
| 473. The Significance of Academia-Industry Collaboration in Translational Research: A Survey of Over 300 PIs Who Have Received Industry Funding NL Davie, P Ovseiko, S Hyde, R Barker, D Gill Molecular Therapy 23, S187-S188, 2015 | | 2015 |
| Gene therapy: barriers to translation N Davie, S Hyde, R Barker, D Gill HUMAN GENE THERAPY 25 (5), 2014 | | 2014 |
| Cell Therapy Industry Market Characteristics: Implications for Clinicians, Investors, Patients and Translational Researchers DA Brindley, NL Davie, EJ Culme-Seymour, BC Reeve, WA Sahlman, ... MOLECULAR THERAPY 20, S294-S294, 2012 | | 2012 |
| Peak Supply: Implications of Serum and Consumable Availability for Clinicians, Researchers, and Commercial Translation NL Davie, DA Brindley, EJ Culme-Seymour, C Mason, DW Smith, ... MOLECULAR THERAPY 20, S293-S294, 2012 | | 2012 |
| Open Innovation In The Life Sciences: A Qualitative Study of Barriers and Enablers M Morys, N Davie, R Pigott, T Kann, R Barker | | |
| Our thanks to all those who have helped with this issue of Regenerative Medicine. Listed below are authors, referees and others who have kindly given their time, effort and … B Abdallah, TV Abramihina, G Adams, R Ahmed, M Ashraf, F Baaijens, ... | | |
| www. futuremedicine. com ER Adams, M Alikani, G Anyfantis, K Appasani, L Armstrong, ... | | |
Jean-François GélinasMcgill在 umontreal.ca 的电子邮件经过验证
Jean-François GélinasMcgill在 umontreal.ca 的电子邮件经过验证
Agata AntepowiczDPhil Student, University of Oxford在 spc.ox.ac.uk 的电子邮件经过验证